During a video conference at the World Government Summit in Dubai, Elon Musk said that he's looking to "find someone else" to lead Twitter by the end of 2023. Between now and then, he said his goal is to "stabilize the organization" and make sure "it's financially in a healthy place."
Musk hinted in December that he would step down eventually but didn't provide specifics.
EU GAS-POWERED CAR BAN
The European Union has approved a law that will ban the sale of gas-powered vehicles from the trading bloc by 2035. In addition, the EU will require cars sold by 2030 to cut emissions by 55 percent from 2021 levels. While some automakers are resisting the rule, others are being proactive. Volkswagen said it will only produce EVs in Europe by 2033.
SUBWAY EXPLORES SALE
After weeks of speculation, Subway has confirmed that it is considering a sale. The Wall Street Journal reported last month that it had hired advisors to look into a deal that could value the company at more than $10 billion. However, "there is no indication of timing or assurance that a sale will occur," the company said in a press release. "J.P. Morgan is advising the company and will conduct the sale exploration process." Subway has more than 37,000 restaurants in more than 100 countries. Same-store sales in North America were up 7.8 percent in 2022.
Jay Hatfield, chief investment officer for ICAP, joined Cheddar News to discuss how markets are reacting to labor market news and what the Federal Reserve will do next in terms of interest rates.
Kristin Cavallari, who first gained fame as a cast member of the MTV reality show Laguna Beach, is now the founder of a beauty company called Uncommon James. Cheddar News anchor Hena Doba took a walk with Cavallari to discuss her many business ventures.
Heardle, the name-that-tune game inspired by the Wordle craze, is being dropped by Spotify less than a year after the music-streaming giant acquired it.
Moderna and Merck & Co. have developed a cancer vaccine that cuts the risk of death or recurrence of most deadly skin cancer by 44 percent compared to Keytruda on its own, according to researchers.
